This trial is unknown!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Myelodysplastic Syndrome
and you are
over 18
years old
2
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

To evaluate the overall response rate of the combination of 5-azacitidine + Lenalidomide in high risk MDS patients (INT-2 and High risk defined by IPSS), and patients with low and int-1 who are considered to be at high risk due to unfavorable additional factors. - To evaluate the safety of the combination of 5-azacitidine + Lenalidomide in high risk MDS patients. - To evaluate the hematological improvement rate. - To evaluate the cytogenetic response rate. - To evaluate the Progression free survival (PFS). - To assess Quality of life.

Provided treatments

  • Drug: 5-Azacytidine and Lenalidomide

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01053806. The sponsor of the trial is Tel-Aviv Sourasky Medical Center and it is looking for 6 volunteers for the current phase.
Official trial title:
A PHASE 2, SINGLE ARM STUDY TO DETERMINE THE SAFETY AND EFFICACY OF AZACITIDINE, AND LENALIDOMIDE IN HIGHER RISK MYELODYSPLASTIC SYNDROME